Several PARP inhibitors are currently approved as monotherapies for the treatment of locally advanced or metastatic breast cancer for patients, with breast cancer harboring germline BRCA1/2 mutations or HER2-negative receptor status [8]. This evidence concerns the gene PARP1 and breast carcinoma.